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Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with unmanipulated
grafts is increasingly adopted for high-risk acute leukemia, with acute graft-versus-host
disease (aGVHD) prophylaxis based on antithymocyte globulin (ATG) or posttransplant
cyclophosphamide (PTCy) as main platforms. No consensus exists on selection criteria over
several haploidentical donors. We evaluated the impact of donor-recipient antigenic and
allelic HLA-A, -B, -C, and -DRB1 mismatches on mismatched haplotype on outcomes of 509
unmanipulated haplo-HSCTs performed for acute leukemia under a PTCy (N 5 313) or ATG
(N 5 196) regimen. An antigenic but not allelic mismatch at the HLA-DRB1 locus was an
independent risk factor for grade$2 aGVHD in PTCy (hazard ratio [HR], 2.0; 95% confidence
interval [CI], 1.2-4.0; P 5 .02) but not in ATG regimens (HR, 1.3; 95% CI, 0.4-3.4; P 5 .6).
Moreover, the hazards of aGVHD were significantly associated with other factors
influencing alloreactivity, including peripheral blood as stem cell source (HR, 2.2; 95% CI,
1.4-3; P , .01), reduced-intensity conditioning (HR, 0.6; 95% CI, 0.4-0.9; P 5 .04), and female
donors (HR, 1.8; 95% CI, 1-3.2; P 5 .05), in PTCy but not ATG regimens. No significant
associations were found between cumulative number of HLA mismatches and GVHD, or
between HLA-matching status and other study end points including transplant-related
mortality, disease-free survival, and relapse. Based on these data, the role of HLA
mismatching on unshared haplotype appears not to be sufficiently prominent to justify its
consideration in haploidentical donor selection. However, the role of HLA matching in
haploidentical HSCT might be modulated by GVHD prophylaxis, calling for further
investigations in this increasingly relevant field.
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Allogeneic hematopoietic stem cell transplantation (HSCT) is a
central component of treatment algorithms for patients with high-
risk acute leukemia.1,2 Donor-recipient HLA compatibility plays a
critical role for successful HSCT. The increasing experience with
unrelated donors and cord blood transplantation highlights the
importance of ascertaining matching at least at HLA-A, -B, -C, and
-DRB1 loci between patient and donor, in order to minimize the
number of mismatches.3-10 Moreover, when only HLA-mismatched
donors are available, clinical data suggest that risks associated with
HLA mismatching are not equivalent across all HLA loci.11-19
HSCT from haploidentical donors, namely family-related donors
who share a 1-haplotype only genotypical identity with the patient, is
a valid option for the sizeable population of patients who lack a
matched related or unrelated donor.20 Haploidentical HSCT (haplo-
HSCT) presents a major immunological barrier because recognition
of the recipient’s mismatched HLA by the donor’s cells provides a
potent stimulus for graft-versus-host disease (GVHD), whereas
recognition of the donor’s mismatched HLA by the recipient’s
immune system leads to graft rejection. Despite this, over recent
years, clinical protocols for unmanipulated T-cell–replete haplo-
HSCT have been successfully developed, using either posttrans-
plant cyclophosphamide (PTCy) or antithymocyte globulin (ATG) as
alternative platforms to harness alloreactivity to the mismatched
HLA haplotype.21-27
Although haploidentical donors are referred to as HLA-haplotype-
mismatched, some recipients who share an HLA haplotype with
their donor are also matched for 1 or more HLA antigens on
the unshared haplotype. Until now, scarce evidence existed on the
relative role of optimal HLA mismatching on the unshared haplotype
in haplo-HSCT. Kasamon et al reported no association between the
degree of HLA disparity on the mismatched haplotype and survival
after nonmyeloablative transplants with PTCy.28 Huo et al reported
that a HLA-B mismatch is associated with an increased risk of acute
GVHD (aGVHD) and transplant-related mortality (TRM), as well as
worse disease-free survival and overall survival (OS) after T-repleted
haplo-HSCT.29 These results were, however, not confirmed in a
more recent study by the same group.30
In order to overcome some limitations of previous single-center
experiences and heterogeneity of included diseases, we performed
a registry-based retrospective study on adult acute leukemia
patients who received an unmanipulated haplo-HSCT, and who
were reported to the Acute Leukemia Working Party (ALWP)
registry of the European Society for Blood and Marrow Trans-
plantation (EBMT).
The aim of the study was to evaluate whether HLA mismatches at
specific loci on the unshared haplotype defined at the antigenic or
the allelic level are associated with divergent clinical risks after
unmanipulated haplo-HSCT.
Methods
Collection of data and inclusion criteria
We included adult patients with de novo acute myeloid leukemia
(AML) and acute lymphoblastic leukemia (ALL) who underwent
an unmanipulated haploidentical bone marrow (BM) or peripheral
blood (PB) transplantation as their first HSCT between January
2007 and December 2014. EBMT centers were asked to provide
HLA typing results for patients and donors at the best available
resolution level, and to provide an update of transplantation out-
comes through specific clinical forms. We selected 509 donor-
recipient pairs for whom we had molecular HLA-A, -B, -C, and
-DRB1 typing at an antigen (ie, first field; N 5 335) or allelic (ie,
second field; N 5 174) resolution level.31 Haploidentical donors
were defined as first-degree relatives who shared 1 HLA haplotype
and were mismatched at 1 or more loci on the unshared haplotype.
The research was approved and conducted within the ALWP of
EBMT. Patients gave informed consent for data entry into the EBMT
registry and for its analysis in accordance with the Declaration of
Helsinki.
HLA-matching status
High-resolution HLA allele typing was available for 174 of 509
pairs (34%), while it was missing in the remaining 335 of
509 pairs (66%).
In order to impute high-resolution matching in these pairs, we
performed an in silico simulation for all donors and patients with the
list of possible diplotypes generated using the German National
Bone Marrow Donor Registry haplotype frequency data set. For
10 pairs, 1 or both of those diplotype lists were empty. For the rest,
the 2 lists were compared (checking up to 800 000 combinations
per pair) to find all possible haploidentical combinations and
to calculate the conditional probability of each haplotype triplet
according to an established algorithm.32,33 Mismatches at low
resolution were directly observable and counted as allele mis-
matches. For each HLA match defined only at low resolution, we
used the respective probability to be matched at high resolution: if it
was $95%, we classified the respective locus to be matched, if
it was #5%, we classified the locus to be mismatched. Donor-
recipient pairs for whom the probability of each locus to be matched
at high resolution was between 6% and 94% were excluded from
the analysis, for a total of 418 pairs included to explore the role of
high-resolution matching on outcomes.
Among the 509 donor-recipient pairs for whom we considered
antigenic HLA matching, 16% were matched at HLA locus A,
11% at locus B, 18% at locus C, and 18% at locus DRB1
(supplemental Table 1). The subgroup of 418 donor-recipient pairs
for whom we could impute high-resolution HLA matching reflected
the overall characteristics of the entire population (supplemental
Table 1). Of them, among pairs with ,4 allelic mismatches, 10%
were matched at HLA locus A, 9% at locus B, 11% at locus C, and
9% at locus DRB1 (supplemental Table 1). The percentages of
antigenic and allelic mismatches at each specific HLA locus in the 2
groups of adoptedGVHD-prophylaxis regimens are shown in Table 1.
In order to evaluate the possible differences on haplo-HSCT
outcomes arising from the direction of HLA mismatches, we defined
HLA mismatches as bidirectional, as host-versus-graft (HVG)
direction only (that means that donor’s alleles were not shared by the
recipient) or graft-versus-host (GVH) direction only (that means that
recipient’s alleles were not shared by the donor). The numbers of
bidirectional, HVG-, or GVH-mismatched pairs for each HLA locus,
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either in the group with antigenic HLA matching, and in the group
with allelic HLA matching, are shown in supplemental Tables 3 and 4.
Clinical end points and statistical methods
Neutrophil engraftment was defined as achievement of an ab-
solute polymorphonuclear leukocyte count .500 cells/mm3 for
3 consecutive days. aGVHD and chronic GVHD (cGVHD) were
defined and scored according to the Glucksberg and Seattle
criteria, respectively.34,35 TRM was defined as death from any
cause while in continuous remission of the primary disease. Re-
lapse was defined as hematological relapse with over 5% mor-
phological blast counts in PB or BM. Leukemia-free survival (LFS)
was defined as the interval from HSCT to either relapse or death in
remission. OS was defined as the interval from HSCT to death
from any cause.
In order to analyze the association between HLA matching and
transplant end points taking into account the 2 main currently used
GVHD-prophylaxis platforms (ie, high-dose PTCy and anti-human
thymocyte immunoglobulin), we conducted our analyses separately
for each of these platforms.
The x2 test was adopted for the comparison of categorical variables
between the 2 GVHD prophylaxis regimens; the Kruskal-Wallis test
was adopted to compare median values of continuous variables
between the 2 groups.
The probabilities of LFS and OS were estimated using the Kaplan-
Meier estimator.36 Cumulative incidences were estimated for
engraftment, GVHD, TRM, and relapse to accommodate competing
risks.37 Relapse was a competing risk for TRM; death from any
cause was a competing risk for engraftment and relapse. Both
relapse and death from any causes were competing risks for GVHD.
Univariate comparisons of survival curves were made using the log-
rank test38; the Gray test was used for univariate comparisons of
cumulative incidence functions.39 Multivariate Cox proportional
hazard models40 were built to adjust for clinical factors associated
with a univariate analysis P value,.15. Covariates included in each
model were: patient age (continuous) and sex, diagnosis (ALL vs
AML), disease status at HSCT, donor sex, host-donor cytomega-
lovirus (CMV) status, intensity of conditioning regimen, stem cell
source (PB vs BM), and transplant center. Interactions between
each covariate and match at each HLA locus were tested and were
not found.
Affirmation of the proportional hazard assumption was met for all
variables. All tests were 2-sided. The type I error rate was fixed at
0.05 for determination of factors associated with time to event.
Adjustments for multiple comparisons were performed. Statistical
analyses were performed with SPSS (SPSS Inc/IBM, Armonk, NY)
and R (R Development Core Team, Vienna, Austria) software.
Results
Patient population and transplant procedures
The main population characteristics are summarized in Table 2.
AML was the main indication for haplo-HSCT in both GVHD-
prophylaxis platforms. At the time of transplant, more than half of the
patients were in complete hematological remission.
Sixty-one percent of patients received high-dose PTCy as selective
alloreactive T-cell depletion, majorly associated with calcineurin
inhibitors and mycophenolate mofetil. Thirty-nine percent of pa-
tients received an ATG-based GVHD prophylaxis (median dose,
30 mg/kg; range, 2.5-80 mg/kg), mostly combining calcineurin inhibitors
or sirolimus and mycophenolate mofetil.
A RIC regimen was more likely adopted in PTCy-based than ATG-
based regimens (59% vs 36%, respectively; P , .01). The applied





HLA-matching status in the entire
population
N 5 313 N 5 196
HLA-A
Antigen mismatch 260 (83) 170 (87) .26
Antigen match 53 (17) 26 (13)
HLA-B
Antigen mismatch 277 (88) 177 (90) .52
Antigen match 36 (12) 19 (10)
HLA-C
Antigen mismatch 260 (83) 157 (80) .40
Antigen match 53 (17) 39 (20)
HLA-DRB1
Antigen mismatch 260 (83) 158 (81) .48
Antigen match 53 (17) 38 (19)
HLA-matching status in subgroup with
HLA high-resolution imputation
N 5 258 N 5 160
HLA-A
Antigen* mismatch 222 (86) 149 (93) .03
Antigen match 36 (14) 11 (7)
Allele† mismatch 229 (88) 151 (94) .07
Allele match 29 (12) 9 (6)
HLA-B
Antigen mismatch 235 (91) 146 (91) .70
Antigen match 23 (9) 14 (9)
Allele mismatch 239 (93) 145 (91) .46
Allele match 19 (7) 15 (9)
HLA-C
Antigen mismatch 226 (88) 133 (83) .19
Antigen match 32 (12) 27 (17)
Allele mismatch 236 (91) 139 (87) .13
Allele match 22 (9) 21 (13)
HLA-DRB1
Antigen mismatch 221 (86) 140 (87) .96
Antigen match 37 (14) 20 (13)
Allele mismatch 236 (91) 148 (92) .71
Allele match 22 (9) 12 (8)
NK alloreactivity in GVL vector
Yes 97 (38) 67 (42) .38
No 161 (62) 93 (58)
*First field HLA typing as reported by the transplant centers.
†Second field HLA typing was reported by the transplant centers in 174 pairs (134 PTCy,
40 ATG). For the remaining 244 pairs, allele level matching was imputed by in silico
simulation as described in “Methods.”
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regimen showed a broad variety, with busulfan- and fludarabine-
based protocols being the most frequently used. Total-body
irradiation was part of the conditioning in 11% of patients treated
with a RIC and 19% of patients treated with a myeloablative
regimen in the PTCy group, whereas it was used in 5% of patients
treated with a RIC and 17% of patients treated with a myeloablative
regimen in the ATG group. The stem cell source was BM for 47% of
patients in the PTCy-based regimens, whereas in the ATG-based
regimens only 28%of patients received BM-derived stem cells (P, .01).
Overall outcomes
The end points in this study were engraftment, 100-day aGVHD,
and 2-year cGVHD, TRM, relapse, LFS, and OS. The cumulative
incidence of neutrophil engraftment at 60 days was 95% 6 2%,
with a median time to engraftment of 17 (range, 3-94) days. The
overall cumulative incidences of grade $2 aGVHD and grade $3
aGVHD at 100 days were 31%6 5% and 12%6 3%, respectively,
in PTCy-based regimens, whereas they were 34% 6 7% and
14% 6 4%, respectively, in ATG-based regimens.
The 2-year cumulative incidence of cGVHD was 27% 6 5%
and 32% 6 7% in PTCy and ATG-based regimens, respectively.
The 2-year cumulative incidence of extensive cGVHD was
11% 6 4% and 13% 6 4% in PTCy and ATG-based regimens,
respectively.
The cumulative incidence of 2-year TRM was 27% 6 5% in PTCy
regimens and 29% 6 6% in ATG regimens. Death was mainly due
Table 2. Patients, donors, and transplant characteristics
PTCy-based GVHD
prophylaxis, N 5 313
ATG-based GVHD
prophylaxis, N 5 196 P
Patient age, median
(range), y
46 (18-77) 44 (18-76) .52
Patient sex, male (%) 182 (58) 110 (56) .62
Time from diagnosis to
transplant, median
(range), mo
9 (2-121) 9 (2-192) .77
AML/ALL, n (%) 233 (74)/80 (26) 140 (71)/56 (29) .45
Disease status at
transplant, n (%)
CR1 117 (37) 65 (33)


















































prophylaxis, N 5 313
ATG-based GVHD
prophylaxis, N 5 196 P
ALL
Standard 18 (41) 20 (43) .80




Donor age, median (range), y 38 (13-70) 39 (12-74) .17
Donor sex, male (%) 170 (54) 101 (52) .54
Female donor/male recipient,
n (%)
79 (25) 55 (28) .49
CMV serostatus, donor/
patient, n (%)
Negative/negative 29 (9) 28 (14) .07
Other combinations 284 (91) 168 (86)
Intensity of conditioning
regimen, n (%)
RIC 140 (59) 70 (36)
MAC 173 (41) 126 (64) ,.01
Donor stem cell source,
n (%)
PB 167 (53) 142 (72)
BM 146 (47) 54 (28) ,.01
CR, complement receptor; MAC, membrane attack complex; MLL, mixed lineage leukemia.
*Cytogenetic analysis was available for 75% of the total population; cytogenetic risk
classification was assigned according to published criteria.47,48
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to infections (53% of patients: bacterial in 54% of cases, viral and
fungal in 28% and 18% of cases, respectively), followed by GVHD
(30%, in half of the cases GVHD was associated with infections).
In the remaining 17% of patients, death was due to other causes
including pulmonary toxicity, sinusoidal obstruction syndrome,
hemorrhage, graft failure, secondary malignancies, and cardiac
toxicity in decreasing order of frequency.
The 2-year cumulative incidence of hematological relapsewas 32%65%
in PTCy regimens and 38% 6 7% in ATG regimens.
Median follow-up for survivors was 23 (range, 1.5-61) months in
patients receiving PTCy regimens, and 36 (range, 1.3-93) months
in those receiving ATG. The probabilities of OS and LFS at 2 years
after transplantation were 44%6 6% and 39%6 6%, respectively,
in the PTCy group, and 40%6 7% and 33%6 7%, respectively, in
the ATG group.
Effect of HLA disparities on clinical outcome
Association between matching at each of the 4 HLA loci (A, B, C,
DRB1) and clinical outcome was analyzed separately in patients
receiving GVHD prophylaxis with PTCy and ATG.
In univariate models, the only significant association found was
for aGVHD, which was significantly higher in the presence of an
antigenic (P 5 .02) but not an allelic (P 5 .33) HLA-DRB1
mismatch in PTCy regimens (Figure 1; supplemental Table 2). This
was reflected also examining the cumulative incidence of aGVHD
selectively on the cohort of patients with high-resolution HLA
imputation, where donor-recipient pairs with an antigen mismatch at
the HLA-DRB1 locus had a trend to higher incidence of grade
2-4 aGVHD compared with HLA-DRB1 antigen-matched pairs
(33% 6 7% vs 19% 6 10%, respectively; P 5 .1).
Consistently, this association was dependent on the directionality of
the mismatch, with significantly higher incidence of aGVHD in
bidirectional or GVH-directed antigenic HLA-DRB1 mismatches
compared with others (P 5 .05; supplemental Table 4). In contrast,
the association between HLA-DRB1 mismatches and aGVHD
could not be appreciated in ATG-based transplants (antigenic
mismatches, P 5 .54; allelic mismatches, P 5 .08) (supplemental
Table 2). The association with HLA-DRB1 locus matching was not
reflective of the total number of HLA mismatches because no
association was found between the incidence of aGVHD and the
cumulative number of antigenic or allelic HLA mismatches on
the unshared haplotype (Figure 2).
For the other clinical end points including engraftment, severe
aGVHD, cGVHD, TRM, relapse, LFS, and OS, no associations with
mismatching at any of the HLA loci could be found, neither in
PTCy nor in ATG regimen (supplemental Table 2). Likewise, no
associations with any outcome end point were found with the
cumulative number of HLA locus mismatches on the unshared
haplotype (supplemental Table 5).
The association between antigenic HLA-DRB1 mismatching and
aGVHD in the PTCy but not in the ATG regimen was confirmed
after adjusting for the significant clinical factors including di-
agnosis, disease status at transplant, stem cell source, donor
sex, conditioning regimen, and recipient age (Table 3). Antigenic
HLA-DRB1 mismatching was an independent predictive factor
for aGVHD after haplo-HSCT with PTCy GVHD prophylaxis,
with significantly higher adjusted hazards compared with HLA-DRB1
matching (hazard ratio [HR], 2.0; 95% confidence interval [CI], 1.2-4.0;
P 5 .03). In contrast, allele level mismatches had no effect.
Consistent with the univariate results, this association was not
observed in patients receiving ATG (Table 4). Similarly, antigenic or
allelic HLA mismatches at the other loci were not independently
associated with any of the other outcome end points regardless of
the GVHD prophylaxis (Tables 3 and 4).
Predicted natural killer (NK) alloreactivity in the graft-versus-
leukemia (GVL) vector according to the “ligand-ligand incompati-
bility” model was tested both in PTCy and in ATG regimens. The
frequencies of pairs with predicted NK alloreactivity are shown in
Table 1. Apparently, pairs with predicted NK alloreactivity in the
PTCy setting seemed to suffer from a higher relapse rate in un-
ivariate analysis (supplemental Table 6); however, this did not
translate into a worse progression-free survival or OS. A subanalysis
performed only on AML patients did not differ from the above-
mentioned results.
Other clinical factors and transplant outcomes
The GVHD prophylaxis regimen modulated the influence of variables
other than HLA-matching status as well. Of note, PB as stem cell
source and myeloablative conditioning were both independently
associated with a higher HR for grade 2-4 aGVHD in the PTCy but
not in the ATG regimens (Tables 3 and 4). Moreover, patients
receiving haploidentical transplantation from female donors (irre-
spective of the patients’ sex) had a higher incidence of grade 2-4
aGVHD in the PTCy but not in the ATG regimens, and experienced a
lower incidence of relapse together with a better OS and LFS in this
group (Figure 3).
In contrast, advanced disease status was an independent factor for
aGVHD in the ATG but not in the PTCy regimens.
Consistent with previous reports,20 advanced disease status at
transplantation was correlated with worse LFS and OS, as well as
with higher rates of relapse and TRM. Finally, a diagnosis of ALL
was associated with worse LFS and OS. Patients suffering from
ALL showed a higher risk of relapse and TRM especially with
ATG-based regimens (Table 3).
Discussion
The present study investigates, for the first time, the role of antigen
and allele HLA mismatches on the clinical outcome of haplo-HSCT
in the context of the 2 majorly used platforms for GVHD prophylaxis,
PTCy and ATG. We show that HLA matching on the unshared
haplotype has a limited impact, with only antigenic HLA-DRB1 mis-
matches significantly associated with the single end point grade$2
aGVHD in transplants performed under the PTCy regimen, and no
association between the cumulative number of HLA mismatches
and outcome. This finding has important practical implications
because several haploidentical donors are available for most pa-
tients and therefore selection based on optimal HLA mismatching
on the unshared haplotype is a tempting concept. Our data do
not provide support for this notion, but rather suggest that HLA
mismatching on the unshared haplotype should not be used as a
major factor in haploidentical donor selection. A possible explana-
tion for this observation could be that the presence of mismatches
at the other loci on the unshared haplotype might blur subtle effects
from matches at individual loci. In line with this concept, the only
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significant association we observed in this study between HLA-
DRB1 mismatching and aGVHD was present at the antigenic but
not at the allelic level, further suggesting that subtle molecular
differences in HLA polymorphism are probably too weak to make a
difference in the clinical setting of haplo-HSCT. Further biological
investigations regarding T-cell alloreactivity in the haploidentical
context are warranted to clarify this point.
Our finding is in contrast with the report by Kasamon et al, in which
no significantly increased risk of aGVHD was associated with
a HLA-DRB1 antigen mismatch on the unshared haplotype in
patients undergoing unmanipulated BM haplo-HSCT with a non-
myeloablative regimen and PTCy as GVHD prophylaxis. This
difference may be dictated by differences in the intensity of the
conditioning regimen and graft source in the study by Kasamon
et al28: as shown in our current analysis, RIC regimens and BM
transplants were both associated with a significant reduction of
aGVHD incidence.
Perhaps the most important finding from our study is that the GVHD
prophylaxis modulates the influence of different variables, including
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Figure 1. Influence of HLA-DRB1 matching status on aGVHD 2-4 in PTCy regimens. (A) Stratification according to antigenic HLA-DRB1 matching (N 5 313). (B)
Stratification according to allelic HLA-DRB1 matching (N 5 258).
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Figure 2. Influence of the number of HLA-A, B, C, DRB1mismatches on aGVHD 2-4 in PTCy regimens. (A) Stratification according to the number of antigenic mismatches
on the unshared haplotype (N 5 313). (B) Stratification according to the number of allelic mismatches on the unshared haplotype (N 5 258).
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Indeed, our data suggest that the risk of aGVHD in PTCy but not
ATG regimens is particularly sensitive to variables influencing T-cell
alloreactivity including not only antigenic HLA-DRB1 matching
status but also stem cell source (with peripheral blood stem cells
likely containing a higher dose of administered T cells), conditioning
intensity, and donor sex. This could reflect the different intrinsic
mechanism by which T cells are eliminated globally or only after
activation in the ATG and the PTCy regimen, respectively. It is
interesting to note that of these variables, only donor sex also had an
influence on relapse risk in PTCy regimen, which was not offset by a
higher TRM and resulted in a disease-free survival advantage. This
beneficial effect might imply peculiar biology of relapse after
haploidentical transplantation which is frequently characterized by
immune escape mechanisms including loss of the unshared HLA
haplotype.41 This could suggest further investigation in the setting
of PTCy platforms, where a globally reduced TRM could tilt the
balance in favor of improved survival in patients grafted from female
donors who could potentially exert a more potent GVL effect possibly
being sensitized by previous pregnancies.
It should be noted that the population included in this study partially
overlaps with the recently published data by Ruggeri et al,27 in
which haplo-HSCT using PTCy was compared with ATG platforms,
showing significantly better LFS, lower incidence of GVHD, and
nonrelapse mortality of the former regimen compared with the latter
in patients with AML in complete remission. In the study by Ruggeri
et al,27 the incidence of aGVHD was not influenced by the stem cell
source or intensity of conditioning regimens in multivariate analysis
adjusting for the adopted GVHD prophylaxis. We hypothesize that
the inclusion of advanced status diseases and ALL patients in our
cohort could partly explain these results. In addition, different
statistical approaches were used in the 2 studies as we separately
analyzed the outcomes according to the 2 GVHD platforms and
focused on match status at each specific HLA locus as a main
effect term in our multivariate model.
Our study has several limitations. In particular, although this is the
largest number of haploidentical transplants in which the HLA effect
and the GVHD prophylaxis effect has been studied so far, the study
might still have limited power to detect subtle associations, in
particular for the transplants with high-resolution allele typing which
represented an 85% subgroup of the entire cohort.
For the same reasons, we were unable to analyze whether transplan-
tation outcomes in our cohort could be influenced by the permissibility of
HLA disparities depending on their immunogenicity. Larger cohorts and
implementation with functional biological assays are needed to examine
whether prioritization of haploidentical donors should be based on
specific mismatches predicted to elicit differential T-cell allorecognition.
Moreover, we were unable to assess the impact of HLA-DQ
and -DP because the relevant typing data were not available. Even
if HLA-DQ is in strong linkage disequilibrium with other HLA class II
loci, we cannot exclude that we missed some information potentially
derived from this locus. For HLA-DP, where the existence of
permissive mismatches based on functional data has been reported
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Figure 3. Influence of clinical variables on aGVHD 2-4 in unmanipulated HSCT. Stratification according to stem cell source (A,D), donor sex (B,E), and intensity of
conditioning regimen (C,F) in PTCy regimens (A-C) or ATG regimens (D-F).
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could not analyze whether this applied also to our haploidentical
cohort. The role of noninherited maternal antigens45 could also not
be investigated here because only a small minority of patients had
a complete HLA familiar typing that could allow assignment of
mismatched haplotypes, given that parents are not usually typed,
particularly for adult patients.
The clinical success obtained with haploidentical transplantation
both with the ATG and the PTCy conditioning regimen platform has
allowed this potentially curative treatment modality to be offered
over recent years to many patients who before were precluded
from it. This has led to a dramatic increase in the clinical application
and relevance of this therapeutic approach not only in Europe, with
over 1500 such transplants performed in 2014 alone,46 but also
worldwide, in particular in the United States and China. The finding
from this study that the role of HLA mismatching on the unshared is
not sufficiently prominent to justify its consideration in haploidentical
donor selection, and that the role of HLA and other variables
appears to be modulated by the adopted GVHD prophylaxis, will be
of clinical relevance in this setting. Retrospective and prospective
confirmation of these data in further homogeneous and well-sized
cohorts are clearly warranted.
Acknowledgments
The authors thank all investigators and data managers for their
dedicatedpatient care.M.M. thanks J. V.Melo (University ofAdelaide,
Adelaide, Australia and Imperial College, London, United Kingdom)
for critical reading of the manuscript.
M.M. acknowledges the support received from the Association
for Training, Education and Research in Hematology, Immunology
and Transplantation (ATERHIT). The Saint-Antoine hospital group
was supported by several grants from theHospital Clinical Research
Program (PHRC) from the French National Cancer Institute (M.M.).
K.F., M.M., and A.N. were supported by the European Commission
Transcan JTC2012 (Cancer12-045-HLALOSS) grant for New
Technologists.
Thanks to the EBMT centers for their participation in this study.
Authorship
Contribution: F.L. designed, performed, and coordinated the re-
search, and collected, analyzed, and interpreted the data; F.L. and
K.F. wrote the manuscript; M.L. designed the research and per-
formed the statistical analyses; F.C., K.F., A.N., and M.M. designed
the research, contributed to data, and commented on the manu-
script; C.R.M. performed the high-resolution HLA imputation; A.R.,
A.B., and M.B. commented on the manuscript; and Z.G., Y.K., W.A.,
B.B., J.T., A.B., D.B., G.M., A.S., M.B., and D.W.B. contributed to
data.
Conflict-of-interest disclosure: The authors declare no compet-
ing financial interests.
ORCID profiles: F.L., 0000-0002-3596-9810.
Correspondence: Francesca Lorentino, Hematology and Bone
Marrow Transplant Unit, San Raffaele Scientific Institute, Via
Olgettina 60, 20132 Milan, Italy; e-mail: lorentino.francesca@hsr.it.
References
1. Thomas ED. Marrow transplantation for malignant disease. Am J Med Sci. 1987;294(2):75-79.
2. Thomas E, Storb R, Clift RA, et al. Bone-marrow transplantation (first of two parts). N Engl J Med. 1975;292(16):832-843.
3. Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma.
N Engl J Med. 1989;320(4):197-204.
4. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313(13):
765-771.
5. Loiseau P, Busson M, Balere ML, et al. HLA Association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B,
-C, -DRB1, or -DQB1 is strongly associated with overall survival. Biol Blood Marrow Transplant. 2007;13(8):965-974.
6. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.
Blood. 2007;110(13):4576-4583.
7. Petersdorf EW, Gooley T, Malkki M, Horowitz M; International Histocompatibility Working Group in Hematopoietic Cell Transplantation. Clinical
significance of donor-recipient HLA matching on survival after myeloablative hematopoietic cell transplantation from unrelated donors. Tissue Antigens.
2007;69(suppl 1):25-30.
8. Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute
leukaemia: a comparison study. Lancet. 2007;369(9577):1947-1954.
9. Kamani N, Spellman S, Hurley CK, et al; National Marrow Donor Program. State of the art review: HLA matching and outcome of unrelated donor
umbilical cord blood transplants. Biol Blood Marrow Transplant. 2008;14(1):1-6.
10. Gluckman E, Rocha V, Arcese W, et al; Eurocord Group. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor
choice. Exp Hematol. 2004;32(4):397-407.
11. Morishima Y, Kashiwase K, Matsuo K, et al; JapanMarrow Donor Program. Biological significance of HLA locus matching in unrelated donor bone marrow
transplantation. Blood. 2015;125(7):1189-1197.
12. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow
transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood. 2004;104(7):1923-1930.
13. Petersdorf EW. Optimal HLA matching in hematopoietic cell transplantation. Curr Opin Immunol. 2008;20(5):588-593.
14. Morishima Y, Sasazuki T, Inoko H, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow
transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002;99(11):4200-4206.




 https://ashpublications.org/bloodadvances/article-pdf/1/11/669/877101/advances006429.pdf by guest on 05 D
ecem
ber 2019
15. Woolfrey A, Klein JP, Haagenson M, et al. HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell
transplantation. Biol Blood Marrow Transplant. 2011;17(6):885-892.
16. Beatty PG, Anasetti C, Hansen JA, et al. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching
for one HLA locus. Blood. 1993;81(1):249-253.
17. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and
II alleles in the donor and recipient. Blood. 1998;92(10):3515-3520.
18. Eapen M, Klein JP, Sanz GF, et al; Eurocord-European Group for Blood and Marrow Transplantation; Netcord; Center for International Blood andMarrow
Transplant Research. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for
leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol. 2011;12(13):1214-1221.
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